Hydrochloric Acid → N-(3-{[2-(3-Methanesulfonyl-phenylamino)-[1,2,4]triazolo[1,5-a]pyridin-8-ylamino]-methyl}-pyridin-2-yl)-N-methyl-methanesulfonamide
반응식
Cl[C:2]1[N:24]=[C:5]2[C:6]([NH:10][CH2:11][C:12]3[C:13]([N:18]([CH3:23])[S:19]([CH3:22])(=[O:21])=[O:20])=[N:14][CH:15]=[CH:16][CH:17]=3)=[CH:7][CH:8]=[CH:9][N:4]2[N:3]=1.[CH3:25][S:26]([C:29]1[CH:30]=[C:31]([NH2:35])[CH:32]=[CH:33][CH:34]=1)(=[O:28])=[O:27].Cl.C1(P(C2CCCCC2)C2C=CC=CC=2C2C=CC=CC=2P(C2CCCCC2)C2CCCCC2)CCCCC1>>[CH3:25][S:26]([C:29]1[CH:30]=[C:31]([NH:35][C:2]2[N:24]=[C:5]3[C:6]([NH:10][CH2:11][C:12]4[C:13]([N:18]([CH3:23])[S:19]([CH3:22])(=[O:21])=[O:20])=[N:14][CH:15]=[CH:16][CH:17]=4)=[CH:7][CH:8]=[CH:9][N:4]3[N:3]=2)[CH:32]=[CH:33][CH:34]=1)(=[O:27])=[O:28]참가 물질
반응물 4
생성물 1
실험 절차
N-(3-{[2-(3-Methanesulfonyl-phenylamino)-[1,2,4]triazolo[1,5-a]pyridin-8-ylamino]-methyl}-pyridin-2-yl)-N-methyl-methanesulfonamide was prepared from N-{3-[(2-chloro-[1,2,4]triazolo[1,5-a]pyridin-8-ylamino)-methyl]-pyridin-2-yl}-N-methyl-methanesulfonamide (75.0 mg, 0.204 mmol) and 3-methanesulfonyl-phenylamine; hydrochloride (39.0 mg, 0.188 mmol) with 2,2′-bis-dicyclohexylphosphanyl-biphenyl (25.0 mg, 0.0457 mmol) as the ligand in a manner analogous to Example 2d. Product isolated as a tan foam (0.010 g, 11%). 1H NMR (400 MHz, CDCl3, δ, ppm): 8.42 (dd, J=4.8, 1.5 Hz, 1H), 8.24 (s, 1H), 7.88-7.83 (m, 3H), 7.53 (d, J=4.9 Hz0, 1H), 7.29 (dd, J=7.7, 4.7 Hz, 1H), 6.96 (s, 1H), 6.72 (t, J=7.5 Hz, 1H), 6.36 (d, J=7.7 HZ, 1H), 5.36 (t, J=6.3 Hz, 1H), 4.78 (d, J=6.1 Hz, 1H), 3.33 (s, 3H), 3.10 (s, 6H). MS=502 (MH)+.
출처 및 근거
- ORD 기록
- ord-d91c2602b32f4039b463cb92789c5476
- 출처 데이터셋
- uspto-grants-2013_08
- 특허 번호
- US08501936B2
반응 노트
불러오는 중…